Management Team

 

Carolyn Rand

Chief Executive Officer

Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses.

Chief Scientific Officer

 

Guy joined Isogenica in January 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development.

Adam Collier

Director of Commercial Development

 

Adam joined Isogenica in May 2015. He brings wide-ranging expertise in the pharmaceutical and biotech industry from senior business development positions at Ablynx nv, Astrazeneca-Medimmune PLC, Leiden University and Horizon Discovery Ltd, where he was Founder Business Development Director.

Director of Antibody Technology Development

Edward joined Isogenica in June 2016 as the Discovery Services Manager, where he oversees the work of his lab-based colleagues.

Associate Director of Alliance Management

Claudia joined Isogenica in January 2009 as Research Scientist, where she started to work on peptide selections against nerve growth factor (NGF).